A Study of ddI in Children With AIDS Who Have Not Had Success With Zidovudine
Not Applicable
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002280
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
The purpose of this study is to make didanosine (ddI) available to children with AIDS who are clinically deteriorating on zidovudine (AZT) or intolerant to AZT and cannot enter the Phase II ddI programs due to protocol exclusion or geographic location.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Bristol - Myers Squibb Co
🇺🇸Wallingford, Connecticut, United States